Factors Associated With Ordering Initial and Follow-up HIV Testinga and Gonorrhea, Chlamydia, or Syphilis Testingb During Active PrEP Intervals
| . | Initial HIV AOR (95% CI) . | Initial Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . | Follow-up HIV AOR (95% CI) . | Follow-up Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . |
|---|---|---|---|---|
| Patient age per 10 y | 0.71 (0.57–0.88) | 0.57 (0.44–0.74) | 0.84 (0.72–0.97) | 0.70 (0.56–0.87) |
| Female vs male at birth | 0.71 (0.30–1.64) | 2.05 (0.64–6.57) | 2.05 (1.10–3.81) | 1.13 (0.44–2.88) |
| Race/ethnicity vs white | ||||
| African American | 1.48 (0.58–3.79) | 2.63 (0.77–9.06) | 0.57 (0.30–1.09) | 0.45 (0.22–0.92) |
| Asian | 0.90 (0.35–2.37) | 1.07 (0.50–2.28) | 0.56 (0.30–1.04) | 0.81 (0.37–1.77) |
| Latino | 0.77 (0.41–1.43) | 1.49 (0.44–5.02) | 0.83 (0.51–1.32) | 1.03 (0.56–1.90) |
| Other | 1.01 (0.48–2.11) | 0.86 (0.38–1.95) | 0.60 (0.34–1.03) | 0.72 (0.31–1.65) |
| PrEP indication vs MSM | ||||
| TGWSM | 0.77 (0.32–1.86) | 1.61 (0.44–5.92) | 1.27 (0.68–2.40) | 2.86 (0.79–10.30) |
| Sero-different relationship | 0.90 (0.42–1.90) | 0.62 (0.26–1.45) | 0.78 (0.50–1.23) | 0.39 (0.19–0.78) |
| Otherc | 2.23 (0.48–2.11) | 0.69 (0.14–3.26) | 0.66 (0.23–1.91) | 0.60 (0.16–2.24) |
| ≥2 PrEP patients per provider | 0.66 (0.34–1.30) | 0.62 (0.29–1.31) | 1.64 (1.05–2.57) | 1.68 (0.92–3.09) |
| Duration of PrEP prescription vs 30 d | ||||
| 31–90 d | — | — | 0.62 (0.27–1.42) | 0.72 (0.25–2.11) |
| >90 d | — | — | 0.37 (0.17–0.81) | 0.61 (0.21–1.79) |
| Active PrEP interval index numberd vs first interval | ||||
| 2nd | — | — | 0.66 (0.44–0.98) | 1.33 (0.81–2.17) |
| ≥3rd | — | — | 0.57 (0.38–0.84) | 1.22 (0.63–2.38) |
| Active panel management program | 1.51 (0.69–3.28) | 4.19 (1.10–15.86) | 2.22 (1.31–3.74) | 1.95 (0.99–3.85) |
| Year vs 2013/14 | ||||
| 2015 | 1.35 (0.69–2.66) | 1.55 (0.78–3.10) | 1.28 (0.69–2.40) | 1.21 (0.64–2.29) |
| 2016 | 2.45 (2.26–5.15) | 6.65 (2.69–16.47) | 1.70 (0.90–3.19) | 2.38 (1.18–4.80) |
| 2017 | 2.62 (0.97–7.08) | 5.68 (1.61–19.98) | 1.36 (0.64–2.87) | 2.22 (0.56–8.82) |
| . | Initial HIV AOR (95% CI) . | Initial Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . | Follow-up HIV AOR (95% CI) . | Follow-up Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . |
|---|---|---|---|---|
| Patient age per 10 y | 0.71 (0.57–0.88) | 0.57 (0.44–0.74) | 0.84 (0.72–0.97) | 0.70 (0.56–0.87) |
| Female vs male at birth | 0.71 (0.30–1.64) | 2.05 (0.64–6.57) | 2.05 (1.10–3.81) | 1.13 (0.44–2.88) |
| Race/ethnicity vs white | ||||
| African American | 1.48 (0.58–3.79) | 2.63 (0.77–9.06) | 0.57 (0.30–1.09) | 0.45 (0.22–0.92) |
| Asian | 0.90 (0.35–2.37) | 1.07 (0.50–2.28) | 0.56 (0.30–1.04) | 0.81 (0.37–1.77) |
| Latino | 0.77 (0.41–1.43) | 1.49 (0.44–5.02) | 0.83 (0.51–1.32) | 1.03 (0.56–1.90) |
| Other | 1.01 (0.48–2.11) | 0.86 (0.38–1.95) | 0.60 (0.34–1.03) | 0.72 (0.31–1.65) |
| PrEP indication vs MSM | ||||
| TGWSM | 0.77 (0.32–1.86) | 1.61 (0.44–5.92) | 1.27 (0.68–2.40) | 2.86 (0.79–10.30) |
| Sero-different relationship | 0.90 (0.42–1.90) | 0.62 (0.26–1.45) | 0.78 (0.50–1.23) | 0.39 (0.19–0.78) |
| Otherc | 2.23 (0.48–2.11) | 0.69 (0.14–3.26) | 0.66 (0.23–1.91) | 0.60 (0.16–2.24) |
| ≥2 PrEP patients per provider | 0.66 (0.34–1.30) | 0.62 (0.29–1.31) | 1.64 (1.05–2.57) | 1.68 (0.92–3.09) |
| Duration of PrEP prescription vs 30 d | ||||
| 31–90 d | — | — | 0.62 (0.27–1.42) | 0.72 (0.25–2.11) |
| >90 d | — | — | 0.37 (0.17–0.81) | 0.61 (0.21–1.79) |
| Active PrEP interval index numberd vs first interval | ||||
| 2nd | — | — | 0.66 (0.44–0.98) | 1.33 (0.81–2.17) |
| ≥3rd | — | — | 0.57 (0.38–0.84) | 1.22 (0.63–2.38) |
| Active panel management program | 1.51 (0.69–3.28) | 4.19 (1.10–15.86) | 2.22 (1.31–3.74) | 1.95 (0.99–3.85) |
| Year vs 2013/14 | ||||
| 2015 | 1.35 (0.69–2.66) | 1.55 (0.78–3.10) | 1.28 (0.69–2.40) | 1.21 (0.64–2.29) |
| 2016 | 2.45 (2.26–5.15) | 6.65 (2.69–16.47) | 1.70 (0.90–3.19) | 2.38 (1.18–4.80) |
| 2017 | 2.62 (0.97–7.08) | 5.68 (1.61–19.98) | 1.36 (0.64–2.87) | 2.22 (0.56–8.82) |
Bolded values indicate statistically significant values at 95% CI.
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; TGWSM, transgender women who have sex with men.
aFor initial testing, measured 30 days before the initial PrEP prescription. For follow-up, examined over 6-month active PrEP prescription intervals, with a gap in PrEP defined as >90 days; both using logistic regression.
bFor initial testing, measured 90 days before and 7 days after the initial prescription. For follow-up, examined over 4-month active PrEP prescription intervals, with a gap in PrEP defined as >90 days; both using logistic regression.
cOther indication includes people who inject drugs and high-risk heterosexual sex.
dPrEP interval index number captures temporal order of active PrEP prescription intervals, that is, the first 4-month interval for a patient would have an index number of 1.
Factors Associated With Ordering Initial and Follow-up HIV Testinga and Gonorrhea, Chlamydia, or Syphilis Testingb During Active PrEP Intervals
| . | Initial HIV AOR (95% CI) . | Initial Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . | Follow-up HIV AOR (95% CI) . | Follow-up Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . |
|---|---|---|---|---|
| Patient age per 10 y | 0.71 (0.57–0.88) | 0.57 (0.44–0.74) | 0.84 (0.72–0.97) | 0.70 (0.56–0.87) |
| Female vs male at birth | 0.71 (0.30–1.64) | 2.05 (0.64–6.57) | 2.05 (1.10–3.81) | 1.13 (0.44–2.88) |
| Race/ethnicity vs white | ||||
| African American | 1.48 (0.58–3.79) | 2.63 (0.77–9.06) | 0.57 (0.30–1.09) | 0.45 (0.22–0.92) |
| Asian | 0.90 (0.35–2.37) | 1.07 (0.50–2.28) | 0.56 (0.30–1.04) | 0.81 (0.37–1.77) |
| Latino | 0.77 (0.41–1.43) | 1.49 (0.44–5.02) | 0.83 (0.51–1.32) | 1.03 (0.56–1.90) |
| Other | 1.01 (0.48–2.11) | 0.86 (0.38–1.95) | 0.60 (0.34–1.03) | 0.72 (0.31–1.65) |
| PrEP indication vs MSM | ||||
| TGWSM | 0.77 (0.32–1.86) | 1.61 (0.44–5.92) | 1.27 (0.68–2.40) | 2.86 (0.79–10.30) |
| Sero-different relationship | 0.90 (0.42–1.90) | 0.62 (0.26–1.45) | 0.78 (0.50–1.23) | 0.39 (0.19–0.78) |
| Otherc | 2.23 (0.48–2.11) | 0.69 (0.14–3.26) | 0.66 (0.23–1.91) | 0.60 (0.16–2.24) |
| ≥2 PrEP patients per provider | 0.66 (0.34–1.30) | 0.62 (0.29–1.31) | 1.64 (1.05–2.57) | 1.68 (0.92–3.09) |
| Duration of PrEP prescription vs 30 d | ||||
| 31–90 d | — | — | 0.62 (0.27–1.42) | 0.72 (0.25–2.11) |
| >90 d | — | — | 0.37 (0.17–0.81) | 0.61 (0.21–1.79) |
| Active PrEP interval index numberd vs first interval | ||||
| 2nd | — | — | 0.66 (0.44–0.98) | 1.33 (0.81–2.17) |
| ≥3rd | — | — | 0.57 (0.38–0.84) | 1.22 (0.63–2.38) |
| Active panel management program | 1.51 (0.69–3.28) | 4.19 (1.10–15.86) | 2.22 (1.31–3.74) | 1.95 (0.99–3.85) |
| Year vs 2013/14 | ||||
| 2015 | 1.35 (0.69–2.66) | 1.55 (0.78–3.10) | 1.28 (0.69–2.40) | 1.21 (0.64–2.29) |
| 2016 | 2.45 (2.26–5.15) | 6.65 (2.69–16.47) | 1.70 (0.90–3.19) | 2.38 (1.18–4.80) |
| 2017 | 2.62 (0.97–7.08) | 5.68 (1.61–19.98) | 1.36 (0.64–2.87) | 2.22 (0.56–8.82) |
| . | Initial HIV AOR (95% CI) . | Initial Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . | Follow-up HIV AOR (95% CI) . | Follow-up Gonorrhea, Chlamydia, or Syphilis AOR (95% CI) . |
|---|---|---|---|---|
| Patient age per 10 y | 0.71 (0.57–0.88) | 0.57 (0.44–0.74) | 0.84 (0.72–0.97) | 0.70 (0.56–0.87) |
| Female vs male at birth | 0.71 (0.30–1.64) | 2.05 (0.64–6.57) | 2.05 (1.10–3.81) | 1.13 (0.44–2.88) |
| Race/ethnicity vs white | ||||
| African American | 1.48 (0.58–3.79) | 2.63 (0.77–9.06) | 0.57 (0.30–1.09) | 0.45 (0.22–0.92) |
| Asian | 0.90 (0.35–2.37) | 1.07 (0.50–2.28) | 0.56 (0.30–1.04) | 0.81 (0.37–1.77) |
| Latino | 0.77 (0.41–1.43) | 1.49 (0.44–5.02) | 0.83 (0.51–1.32) | 1.03 (0.56–1.90) |
| Other | 1.01 (0.48–2.11) | 0.86 (0.38–1.95) | 0.60 (0.34–1.03) | 0.72 (0.31–1.65) |
| PrEP indication vs MSM | ||||
| TGWSM | 0.77 (0.32–1.86) | 1.61 (0.44–5.92) | 1.27 (0.68–2.40) | 2.86 (0.79–10.30) |
| Sero-different relationship | 0.90 (0.42–1.90) | 0.62 (0.26–1.45) | 0.78 (0.50–1.23) | 0.39 (0.19–0.78) |
| Otherc | 2.23 (0.48–2.11) | 0.69 (0.14–3.26) | 0.66 (0.23–1.91) | 0.60 (0.16–2.24) |
| ≥2 PrEP patients per provider | 0.66 (0.34–1.30) | 0.62 (0.29–1.31) | 1.64 (1.05–2.57) | 1.68 (0.92–3.09) |
| Duration of PrEP prescription vs 30 d | ||||
| 31–90 d | — | — | 0.62 (0.27–1.42) | 0.72 (0.25–2.11) |
| >90 d | — | — | 0.37 (0.17–0.81) | 0.61 (0.21–1.79) |
| Active PrEP interval index numberd vs first interval | ||||
| 2nd | — | — | 0.66 (0.44–0.98) | 1.33 (0.81–2.17) |
| ≥3rd | — | — | 0.57 (0.38–0.84) | 1.22 (0.63–2.38) |
| Active panel management program | 1.51 (0.69–3.28) | 4.19 (1.10–15.86) | 2.22 (1.31–3.74) | 1.95 (0.99–3.85) |
| Year vs 2013/14 | ||||
| 2015 | 1.35 (0.69–2.66) | 1.55 (0.78–3.10) | 1.28 (0.69–2.40) | 1.21 (0.64–2.29) |
| 2016 | 2.45 (2.26–5.15) | 6.65 (2.69–16.47) | 1.70 (0.90–3.19) | 2.38 (1.18–4.80) |
| 2017 | 2.62 (0.97–7.08) | 5.68 (1.61–19.98) | 1.36 (0.64–2.87) | 2.22 (0.56–8.82) |
Bolded values indicate statistically significant values at 95% CI.
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; TGWSM, transgender women who have sex with men.
aFor initial testing, measured 30 days before the initial PrEP prescription. For follow-up, examined over 6-month active PrEP prescription intervals, with a gap in PrEP defined as >90 days; both using logistic regression.
bFor initial testing, measured 90 days before and 7 days after the initial prescription. For follow-up, examined over 4-month active PrEP prescription intervals, with a gap in PrEP defined as >90 days; both using logistic regression.
cOther indication includes people who inject drugs and high-risk heterosexual sex.
dPrEP interval index number captures temporal order of active PrEP prescription intervals, that is, the first 4-month interval for a patient would have an index number of 1.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
